COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREVENTION INTERVENTIONS IN CHILDREN: A MODEL COMPARISON STUDY

被引：0
|
作者：
Li, X. X. [1 ]
Hodgson, D. [2 ]
Flaig, J. [3 ]
Kieffer, A. [4 ]
Herring, W. [5 ]
Beyhaghi, H. [6 ]
Williem, L. [1 ]
Jit, M. [2 ]
Bilcke, J. [1 ]
Beutels, P. [1 ]
机构：
[1] Univ Antwerp, Antwerp, Van, Belgium
[2] London Sch Hyg & Trop Med, London, England
[3] Epidemiol & Modeling Infect Dis EPIMOD, Lyon, France
[4] Sanofi, Lyon, France
[5] RTI Hlth Solut, Res Triangle Pk, NC USA
[6] Novavax Inc, Durham, NC USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE622
引用
收藏
页码：S178 / S178
页数：1
相关论文
共 50 条
  • [21] Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
    Xiao Li
    Lander Willem
    Marina Antillon
    Joke Bilcke
    Mark Jit
    Philippe Beutels
    BMC Medicine, 18
  • [22] Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
    Li, Xiao
    Willem, Lander
    Antillon, Marina
    Bilcke, Joke
    Jit, Mark
    Beutels, Philippe
    BMC MEDICINE, 2020, 18 (01)
  • [23] Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
    Mac, Stephen
    Sumner, Amanda
    Duchesne-Belanger, Samuel
    Stirling, Robert
    Tunis, Matthew
    Sander, Beate
    PEDIATRICS, 2019, 143 (05)
  • [24] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab - Reply
    Sorbero, Melony E. S.
    ElHassan, Nahed O.
    Hall, Caroline B.
    Stevens, Timothy P.
    Dick, Andrew W.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 520 - 520
  • [25] Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications
    Hampp, Christian
    Kauf, Teresa L.
    Saidi, Arwa S.
    Winterstein, Almut G.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2011, 165 (06): : 498 - 505
  • [26] The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly
    Gessner, BD
    VACCINE, 2000, 18 (15) : 1485 - 1494
  • [27] Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
    Ishiwada, Naruhiko
    Akaishi, Rina
    Kobayashi, Yasuhiro
    Togo, Kanae
    Yonemoto, Naohiro
    Matsuo, Moe
    Kaneko, Shinnosuke
    Law, Amy W.
    Kamei, Kazumasa
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (07) : 1665 - 1682
  • [28] Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis
    Nazareno, Allen L.
    Wood, James G.
    Muscatello, David J.
    Homaira, Nusrat
    Hogan, Alexandra B.
    Newall, Anthony T.
    VACCINE, 2025, 46
  • [29] COST-EFFECTIVENESS OF NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY TRACT DISEASE (RSV LRTD) IN THE US BIRTH COHORT
    Kieffer, A.
    Sardesai, A.
    Musci, R.
    Beuvelet, M.
    De Su, Tribaldos Causadias M.
    Lee, J. K. H.
    Rizzo, C.
    Greenberg, M.
    VALUE IN HEALTH, 2023, 26 (12) : S135 - S135
  • [30] Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
    Gebretekle, Gebremedhin B.
    Yeung, Man Wah
    Ximenes, Raphael
    Cernat, Alexandra
    Simmons, Alison E.
    Killikelly, April
    Siu, Winnie
    Rafferty, Ellen
    Brousseau, Nicholas
    Tunis, Matthew
    Tuite, Ashleigh R.
    VACCINE, 2024, 42 (21)
12345